Inflammatory Bowel Diseases (IBD)
Inflammatory Bowel Diseases
Feature Article
Exclusive Enteral Nutrition Significantly Alters Gut Microbiota in IBD
Crohn disease and ulcerative colitis comprise the 2 primary subtypes of inflammatory bowel diseases (IBD). IBD currently has no known cure and whose pathogenesis is not well understood. However, an increasing amount of research points to genetic risk factors combined with antibiotic use and changes in intestinal microbiota as triggers for the onset of IBD.1,2…
Latest News
Intestinal Ultrasound Efficacy in Ulcerative Colitis Assessed
The study gives rise to the assumption that monitoring bowel wall thickness alone has the potential to predict therapeutic response and future prospective studies are necessary to determine the value of intestinal ultrasound in the prediction of short- and long-term ulcerative colitis responses and outcomes.
Dual Therapy for Clostridioides difficile Infection Not Superior to Vancomycin Alone
Dual therapy with intravenous metronidazole and oral vancomycin is not superior to oral vancomycin alone in the treatment of Clostridioides difficile infections.
Worsening Symptoms, Heart Failure in UC Patient Treated With Mesalamine
The patient had been diagnosed with mild-to-moderate ulcerative colitis (UC) a month prior to presentation for which she was prescribed oral mesalamine.
Prescribing Patterns for Initiation of Ustekinumab in Crohn Disease
Prescribing patterns among patients treated with ustekinumab for Crohn disease were presented at the 2019 AIBD Annual Meeting.
Etrolizumab Improves Histologic Disease Activity in Ulcerative Colitis
Etrolizumab is an investigational humanized monoclonal anti-ß7 antibody with a dual mechanism of action.
Reasons for Certolizumab Use Examined in Patients With Crohn Disease
To better understand the real-world prescribing patterns of certolizumab, researchers collected data from a large multicenter gastroenterology private practice dating back to 2008.
Impact of Tofacitinib on Extraintestinal Symptoms in UC Patients Examined
Treatment with tofacitinib appears to have little impact on extraintestinal manifestations (EIMs) in patients with moderate to severe ulcerative colitis (UC) and might even improve them, according to an analysis of the OCTAVE program. Findings were presented at the 2019 AIBD Annual Meeting in Orlando, Florida.
Ontamalimab Induces Clinical, Symptomatic Remission in Ulcerative Colitis Patients
Treatment with ontamalimab was associated with both clinical and symptomatic remission in patients with ulcerative colitis (UC), according to data presented at the 2019 AIBD Annual Meeting held in Orlando, Florida.
Investigational Subcutaneous Vedolizumab Shows Similar Efficacy to IV: Network Meta-Analysis
Based on the network meta-analysis, study authors reported similar efficacy and safety profiles for the IV and SC formulations of vedolizumab.
Mental Health Services Underutilized in Pediatric IBD Patients
Inflammatory bowel disease (IBD) diagnosis appears to be associated with high levels of anxiety and depression in children, however, new study findings presented at the 2019 AIBD Annual Meeting suggest that many of these patients may not be receiving appropriate mental health services.
ED Visits, Hospitalization Trends Examined in Patients With IBD
Trends in the utilization of emergency department (ED) care and hospitalization among patients with inflammatory bowel disease (IBD) were investigated in a new study.
Safety of IV Iron Products Compared in Patients With IBD
The safety profiles of various IV iron products were compared in a study involving patients with inflammatory bowel disease IBD being treated for iron deficiency anemia.
Effects of Adalimumab, Infliximab in Biologic-Naive IBD Patients
Treatment with adalimumab or infliximab in biologic-naive patients with Crohn disease or ulcerative colitis demonstrated similar outcomes on Patient-Reported Outcomes Measurement Information System measures and rates of corticosteroid-free remission.
PPI Use and Periodontal Disease: What’s the Link?
“The data indicate that more conservative periodontal therapy might initially be considered for IBD patients with advanced periodontal disease for whom PPI are prescribed as a component of their IBD treatment,” the authors concluded.
Tofacitinib vs Vedolizumab: Short-Term Efficacy Compared in Ulcerative Colitis
In patients with ulcerative colitis (UC), tofacitinib, a Janus kinase inhibitor, was associated with improved short-term efficacy, when compared with vedolizumab, an integrin receptor antagonist. Findings were presented at the Advances in Inflammatory Bowel Disease (AIBD) 2019 meeting in Orlando, Florida.
Timing of Biologic/JAK Inhibitor Treatment Initiation in IBD Patients Examined
According to new research over 1 in 5 patients with inflammatory bowel disease (IBD) should have started treatment with an advanced systemic therapy earlier in their disease.
Combination Biologics or Small Molecules vs Biologic Monotherapy in IBD
Combination biologic therapy may be an effective treatment option for patients with inflammatory bowel disease (IBD) who are refractory or have a concomitant autoimmune disease that is inadequately controlled by biologic monotherapy.
Case Highlights Novel Approach to Treatment of UC, Psoriatic Arthritis
A recently published report presented at the 2019 AIBD Annual Meeting in Orlando, FL, discussed the case of a patient who developed ulcerative colitis (UC) following treatment with Secukinumab for her psoriatic arthritis and highlighted a novel approach for the management of both of her conditions simultaneously.
Biosimilar BI 695501 Comparable to Reference Product in Crohn Disease
Biosimilar BI 695501 demonstrated non-inferior efficacy and similar safety profile compared with the reference product adalimumab in patients with active Crohn disease.
Vedolizumab Shows Long-Term Efficacy and Safety Data in Patients with Active UC and CD
Vedolizumab demonstrated long-term effectiveness and favorable safety profile in patients with moderately-to-severely active ulcerative colitis and Crohn Disease.
Want to read more?
Please login or register first to view this content.
Next post in Inflammatory Bowel Diseases (IBD)
